Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the best biotech stocks to invest in now.
Amicus Therapeutics Inc. (FOLD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 21,464,527 | $175,150,540 | -12% | 6.17% |
| 2. | VenBio Select Advisor Kurt Von Emster | 20,500,000 | $167,280,000 | -12% | 2.61% |
| 3. | Redmile Group Jeremy Green | 9,533,669 | $77,794,739 | +36% | 7.35% |
| 4. | Citadel Investment Group Ken Griffin | 7,839,543 | $63,970,671 | -5% | 0.01% |
| 5. | Palo Alto Investors William Leland Edwards | 7,345,002 | $59,935,216 | -5% | 11.41% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.49 | 1,500 | $15,735.00 | 65,082 | 2021-11-01 | Filing | |
| $9.56 | 1,500 | $14,346.00 | 63,582 | 2021-10-01 | Filing | |
| $11.41 | 1,500 | $17,115.00 | 62,082 | 2021-09-01 | Filing | |
| $9.28 | 1,500 | $13,920.00 | 60,582 | 2021-08-02 | Filing | |
| $9.24 | 1,500 | $13,861.20 | 47,467 | 2021-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.00 | 400 | $4,000.00 | 1,150,657 | 2025-02-19 | Filing | |
| $10.02 | 7,500 | $75,124.50 | 886,654 | 2024-12-02 | Filing | |
| $12.50 | 7,901 | $98,800.42 | 886,654 | 2024-11-06 | Filing | |
| $11.46 | 7,500 | $85,959.75 | 886,654 | 2024-11-01 | Filing | |
| $10.60 | 7,500 | $79,492.50 | 886,654 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 29,200,617 | $238,277,035 | 0.05% | |
| 2. | 29,050,621 | $237,053,067 | 0% | |
| 3. | 27,823,772 | $227,041,980 | 0% | |
| 4. | 14,778,651 | $120,593,792 | 0.34% | |
| 5. | 9,519,019 | $77,675,195 | 0% |
News See All
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
10 Best Low Priced Biotech Stocks to Buy Now
On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics First Quarter 2025 Financial Results Conference Call and Webcast.
11 Best Guru Stocks to Buy According to Wall Street Analysts
Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.
10 Best Low Priced Growth Stocks To Invest In
Low priced stocks usually fall under the small to mid-cap size category.
10 Best Low Cost Stocks to Buy According to Billionaires
Markets are wobbling, and panic is becoming the headline. At times when stocks are tumbling, headlines are filled with forecasts that cause anxiety for investors. But it's not new.
12 Best Nasdaq Stocks Under $20 to Buy Now
The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13.
12 Stocks Under $10 With High Upside Potential
Small-cap stocks in the U.S. have suffered as the broader market is under pressure due to the ongoing tariff policy transition.
10 Oversold Pharma Stocks to Buy According to Analysts
On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity...
Billionaire Hedge Funds
